The Food and Drug Administration (FDA) has approved Tzield (teplizumab-mzwv) injection, a new treatment that can delay the onset of stage 3 type 1 diabetes (T1D) in adults and pediatric patients eight years and older who have stage 2 T1D.
Tzield is the first disease-modifying therapy for T1D, a d
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
